Sep 11, 2023 / 08:00PM GMT
Ramakanth Swayampakula - H.C. Wainwright & Co. - Analyst
Greetings, and thanks for joining us to have a conversation with Laurent Levy, CEO of Nanobiotix. Nanobiotix is developing a radio enhancer, NBTXR3, which is hafnium oxide nanoparticles that can induce radiotherapy upon injecting into the tumor. The drug has received CE mark in 2019. Recently the company forged a global co-development and co-commercialization agreement with Janssen Pharmaceuticals.
To learn more about the drug, the co-development agreement, and the clinical development strategy, I welcome Laurent to the fireside chat. Laurent, glad to see you and appreciate you accepting our invitation to talk to our audience.
Questions and Answers:
Ramakanth Swayampakula - H.C. Wainwright & Co. - AnalystSo Laurent, when you started the company back in 20 years ago, so what was the problem that you were trying to solve? And since you have -- since then, what sort of achievements has the company made?
Laurent Levy - Nanobiotix S.A. - CEO
Trustpilot
